IL6 and COVID-19: Theoretically, the monoclonal antibody against IL-6, tocilizumab, could have an anti-inflammatory effect in NASH, as it is effective against hyperinflammatory states of COVID-19, but it has also demonstrated liver enzyme elevations and DILI in a few cases [55].